Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.

ABSTRACT:

Background

In major bleeding events, the new direct oral anticoagulants pose a great challenge for physicians. The aim of the study was to test for ex vivo reversal of the direct oral anticoagulant rivaroxaban with various non-specific reversal agents: prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (aPCC), recombinant activated factor VII (rFVIIa), and fibrinogen concentrate (FI).

Methods

Blood was obtained from healthy volunteers and from patients treated with rivaroxaban. Blood samples from healthy volunteers were spiked with rivaroxaban to test the correlation between rivaroxaban concentration and coagulation tests. Patient blood samples were spiked with various concentrations of the above-mentioned agents and analysed using thromboelasto

SUBMITTER: Schenk B 

PROVIDER: S-EPMC5091332 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature